Skip to main content
×
Home
    • Aa
    • Aa
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 3
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Cameron, Chris Kelly, Shannon Hsieh, Shu-Ching Murphy, Meghan Chen, Li Kotb, Ahmed Peterson, Joan Coyle, Doug Skidmore, Becky Gomes, Tara Clifford, Tammy and Wells, George 2015. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis. Headache: The Journal of Head and Face Pain, Vol. 55, p. 221.


    Coyle, Doug Lee, Karen M. Mamdani, Muhammad Sabarre, Kelley-Anne and Tingley, Kylie 2015. Reimbursement-Based Economics - What Is It and How Can We Use It to Inform Drug Policy Reform?. Headache: The Journal of Head and Face Pain, Vol. 55, p. 236.


    Woldeamanuel, Y. W. Rapoport, A. M. and Cowan, R. P. 2014. What Is the Evidence for the Use of Corticosteroids in Migraine?. Current Pain and Headache Reports, Vol. 18, Issue. 12,


    ×
  • International Journal of Technology Assessment in Health Care, Volume 28, Issue 4
  • October 2012, pp. 382-389

COST-EFFECTIVENESS OF ORAL TRIPTANS FOR ACUTE MIGRAINE: MIXED TREATMENT COMPARISON

  • Christian Asseburg (a1), Piia Peura (a2), Tuija Oksanen (a3), Juha Turunen (a4), Timo Purmonen (a5) and Janne Martikainen (a6)
  • DOI: http://dx.doi.org/10.1017/S0266462312000517
  • Published online: 01 September 2012
Abstract

Background: The cost-effectiveness of triptans in the treatment of migraine has not been assessed since generic sumatriptan entered the Finnish market in 2008.

Methods: Using systematic review and mixed treatment comparison, the effectiveness of triptans was estimated with regard to 2-hour response, 2-hour pain-free, recurrence, and any adverse event, using published clinical data. Direct and indirect costs (2010 EUR, societal perspective) and quality-adjusted life-years (QALYs) were evaluated over one acute migraine attack using a decision-tree model.

Results: The meta-analysis combined data from fifty-six publications. The highest probability of achieving the primary outcome, “sustained pain-free, no adverse event” (SNAE), was estimated for eletriptan 40 mg (20.9 percent). Sumatriptan 100 mg was the treatment with lowest estimated costs (€20.86), and the incremental cost-effectiveness ratio of eletriptan 40 mg compared with sumatriptan 100 mg was €43.65 per SNAE gained (€19,659 per QALY gained).

Conclusion: Depending on the decision-maker's willingness-to-pay threshold, either sumatriptan 100 mg or eletriptan 40 mg is likely to be cost-effective.

Copyright
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1.LR Arends , Vokó Z, Stijnen T. Combining multiple outcome measures in a meta-analysis: An application. Stat Med. 2003;22:13351353.

2.DK Arulmozhi , A Veeranjaneyulu , SL Bodhankar . Migraine: Current concepts and emerging therapies. Vascul Pharmacol. 2005;43:176187.

4.N Buscemi , L Hartling , B Vandermeer , L Tjosvold , TP Klassen . Single data extraction generated more errors than double data extraction in systematic reviews. J Clin Epidemiol. 2006;59:697703.

5.MD Ferrari , PJ Goadsby , KI Roon , RB Lipton . Triptans (serotonin, 5-HT1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22:633658.

6.PJ Goadsby , T Sprenger . Current practices and future directions in the prevention and acute management of migraine. Lancet Neurol. 2010;9:285298.

8.JPT Higgins , SG Thompson , DJ Spiegelhalter . A re-evaluation of random-effects meta-analysis. J R Statist Soc A Stat Soc. 2009;172:137159.

10.E Loder . Triptan therapy in migraine. N Engl J Med. 2010;363:6370.

11.G Lu , AE Ades . Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23:31053124.

16.J Ramsberg , M Henriksson . The cost-effectiveness of oral triptan therapy in Sweden. Cephalalgia. 2007;27:5462.

17.A Sutton , AE Ades , N Cooper , K Abrams . Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics. 2008;26:753767.

19.M Thompson , M Gawel , B Desjardins , N Ferko , D Grima . An economic evaluation of rizatriptan in the treatment of migraine. Pharmacoeconomics. 2005;23:837850.

20.R Xu , RP Insinga , W Golden , XH Hu . EuroQol (EQ-5D) health utility scores for patients with migraine. Qual Life Res. 2011;20:601608.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Journal of Technology Assessment in Health Care
  • ISSN: 0266-4623
  • EISSN: 1471-6348
  • URL: /core/journals/international-journal-of-technology-assessment-in-health-care
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords: